Target- |
MechanismCell replacements |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismStem cell replacements |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism
The intent of this clinical study is to answer the questions:
Is the proposed treatment safe
Is treatment effective in improving the disease pathology of patients with Autism.
/ WithdrawnNot Applicable An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous ADSC Implantation by a Catheter Delivery System In Patients During the Subacute Recovery Phase of ST-Elevation MI
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe? and 2) Is treatment effective in improving cardiac function and clinical outcomes?
/ WithdrawnNot Applicable An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis
The intent of this clinical study is to answer the questions:
Is the proposed treatment safe
Is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes?
100 Clinical Results associated with Ageless Regenerative Institute LLC
0 Patents (Medical) associated with Ageless Regenerative Institute LLC
100 Deals associated with Ageless Regenerative Institute LLC
100 Translational Medicine associated with Ageless Regenerative Institute LLC